CRAB’s statistical team is comprised of statisticians with a wide variety of backgrounds and expertise. Our statistical team has decades of experience in the field of oncology clinical development, with specific experience designing, analyzing, reporting, and representing important findings in the field of oncology. Many of our staff have affiliate appointments at the Fred Hutchinson Cancer Research Center and the Biostatistics Department at the University of Washington.
We have experience in the design and analysis of a wide variety of oncology clinical trials with associated translational data. Trials include single- institution oncology trials, cooperative group SWOG trials, as well as Phase I-IV industry sponsored trials. In addition to designing and analyzing trials, CRAB statisticians are involved with cutting-edge methodological research on novel clinical trial designs and have led or contributed to many publications in that area.
Antje Hoering, Ph.D., President and Chief Executive Officer, brings distinguished academic and scientific achievements, executive leadership and over 15 years of experience to the role. She presently serves as the lead statistician for the SWOG Myeloma Committee and is an active member of the Myeloma Steering Committee for the National Clinical Trials Network. Dr. Hoering also serves as the Director of the Biostatistics Core for a SPORE grant funded through the Sarcoma Alliance for Research Through Collaboration, and is the Co-Director of the Biostatistics Core for a Program Project through the Myeloma Institute for Research and Therapy. Dr. Hoering also serves as a consultant on a variety of industry sponsored studies, including a phase III registration trial and has been the biostatistics representative on two Type B meetings with the FDA. Dr. Hoering holds affiliate appointments at the Fred Hutchinson Cancer Research Center and the Biostatistics Department of the University of Washington. Read more about Antje on our Management Team page. CV pdf
John Crowley, Ph.D, Chief of Strategic Alliances, brings four decades of experience in Biostatistics to his role as Chief of Strategic Alliances. He founded CRAB in 1997, and served as President and CEO until 2014. Dr. Crowley was the Director of the Statistical Center for SWOG, co-located at CRAB and the Fred Hutchinson Cancer Research Center from 1984 to 2012. Building on that expertise, under Dr. Crowley’s lead CRAB also serves as the Statistical Center for the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. CRAB also works intimately with the International Association for the Study of Lung Cancer, the International Myeloma Foundation and Sarcoma Alliance Research Through Collaboration. Read more about these research groups in Our Key Partnerships. Read more about John on our Management Team page. CV pdf
William Barlow, Ph.D., Senior Biostatistician, is the lead statistician for the SWOG Breast Committee designing, conducting, and analyzing breast cancer clinical trials. In the latest study to be launched nationwide we will study whether the 21-gene recurrence assay can predict whether chemotherapy is beneficial in women with early stage node-positive, hormone receptor positive breast cancer. This study will include testing tumors in 9,000 women to identify 4,000 women who meet the requirements for the trial. Such biomarker evaluations can direct therapy – to this end he is involved in a grant with the Fred Hutchinson Cancer Research Center to develop methods for testing biomarkers in the clinical setting. Other interests include breast cancer screening, other clinical prognostic and predictive markers, trial design, and efficient sampling methods for biomarker evaluation. CV pdf
Pingping Qu, Ph.D., Senior Biostatistician, is the CRAB expert on high-dimensional data analysis. She analyzes large amounts of Gene Expression Profile (GEP) data, often taken at various time-points of a treatment protocol, correlating these data to clinically relevant outcomes. She also has extensive expertise in developing risk scores based on GEP data. Her experience also includes the analysis of single nucleotide (SNP) data and proteomics data.
Lynn Shemanski, Ph.D., Senior Biostatistician, received her Master's Degree in Statistics from UC-Berkeley, and her Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill. She has more than 25 years experience working in clinical trials. As a Research Scientist at the University of Washington, she was the lead statistician responsible for design, supervision and analysis of Quality Control studies for carotid ultrasound, MRI and echocardiography reading centers for the Cardiovascular Health Study (CHS), a large epidemiological study of cardiovascular disease in the elderly. As Senior Biostatistician at Cell Therapeutics, Inc. (CTI), Dr. Shemanski designed and performed analysis for all Phase II and Phase III oncology clinical trials, using two-stage, superiority or non-inferiority study designs. While at CTI, Lynn was responsible for the statistical sections for the Integrated Safety and Efficacy Sections for a successful NDA submission. At Axio Research, Dr. Shemanski served as Director of Biostatistics and was the Principal Investigator for the statistical analysis center for Phase I, II and III clinical trials supported by the National Institute on Drug Abuse (NIDA). Prior to joining CRAB, Dr. Shemanski was the Director of Biostatistics at Poniard Pharmaceuticals and Director of Biometrics at Zymogenetics, a subsidiary of Bristol-Myers Squibb. In these capacities, Lynn supervised statistical programmers and data management personnel and served as primary statistician on several clinical trials in oncology. At CRAB, Lynn specializes in Clinical Research Services Projects and provides statistical oversight for the Stand Up to Cancer Pancreatic Cancer Research Team and Clinical Trial Consortium projects. CV pdf